Dogwood Therapeutics, Inc. (DWTX) - Total Liabilities
Based on the latest financial reports, Dogwood Therapeutics, Inc. (DWTX) has total liabilities worth $14.61 Million USD as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore how efficiently does Dogwood Therapeutics, Inc. generate cash to assess how effectively this company generates cash.
Dogwood Therapeutics, Inc. - Total Liabilities Trend (2018–2024)
This chart illustrates how Dogwood Therapeutics, Inc.'s total liabilities have evolved over time, based on quarterly financial data. See DWTX net asset value for net asset value and shareholders' equity analysis.
Dogwood Therapeutics, Inc. Competitors by Total Liabilities
The table below lists competitors of Dogwood Therapeutics, Inc. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Sino Tactful Co Ltd
TWO:5481
|
Taiwan | NT$362.13 Million |
|
Uniflex Technology Inc
TW:3321
|
Taiwan | NT$1.95 Billion |
|
FASOO.COM Co Ltd
KQ:150900
|
Korea | ₩12.12 Billion |
|
Milae Bioresources Co. Ltd
KQ:218150
|
Korea | ₩16.21 Billion |
|
Bonia Corporation Bhd
KLSE:9288
|
Malaysia | RM254.88 Million |
|
Barratt Redrow plc
LSE:BTRW
|
UK | GBX3.50 Billion |
|
Alpha Exploration Ltd
V:ALEX
|
Canada | CA$395.82K |
Liability Composition Analysis (2018–2024)
This chart breaks down Dogwood Therapeutics, Inc.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Dogwood Therapeutics, Inc. market cap and net worth.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 4.49 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.19 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.16 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Dogwood Therapeutics, Inc.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Dogwood Therapeutics, Inc. (2018–2024)
The table below shows the annual total liabilities of Dogwood Therapeutics, Inc. from 2018 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $30.03 Million | +8274.67% |
| 2023-12-31 | $358.55K | -65.63% |
| 2022-12-31 | $1.04 Million | -18.22% |
| 2021-12-31 | $1.28 Million | -16.73% |
| 2020-12-31 | $1.53 Million | -70.87% |
| 2019-12-31 | $5.26 Million | +296.46% |
| 2018-12-31 | $1.33 Million | -- |
About Dogwood Therapeutics, Inc.
Dogwood Therapeutics, Inc., a development-stage biotechnology company, focuses on the development of medicine to treat pain and fatigue-related disorders. Its lead product candidates include IMC-1, a fixed dose combination of famciclovir and celecoxib that has completed Phase 2b clinical trial to treat fibromyalgia; Halneuron, which is in Phase 2b clinical trial for the treatment of chemotherapy-… Read more